WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ... project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 ...

The entire clinical development process may last 6-11 years. WuXi’s phase 1 and phase ... can’t manufacture everything in-house. Biologics manufacturing requires quality certificates and ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...

Unveiled last year, the Singapore site will include manufacturing ... nearly 18.7 billion yuan ($2.6 billion). Taking COVID-related projects out of the mix, WuXi Biologics total 2024 revenue ...

SINGAPORE] Global markets have been nothing but volatile on the back of tariff-induced swings – but China stocks were an outlier last week. Read more at The Business Times.

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio ... recent autoimmune disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled ...

Amogy, a provider of mature, scalable, and efficient ammonia-to-power solutions, today announced the first pilot plant deployment of its advanced ammonia cracking catalyst with JGC Holdings ...